Use of a serenoa repens extract for the production of a medicament to treat prostate cancer
CA 2370775 C · Owner: Pierre Fabre Medicament · Inventors: Raynaud, Jean-Pierre; Fabre, Pierre; Cousse, Henri
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of a lipido-sterolic Serenoa Repens extract for the production of a medicament which is administered in an isolated manner or in an associated manner in a simultaneous, separated or staggered manner with prostatectomy, radiotherapy and/or hormonotherapy in order to prevent and/or treat prostate cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 30, 2000 and granted June 21, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 30, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 30, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.